---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-237199"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-05-22T21:24:41+00:00"
generated_at: "2026-05-22T21:28:16.063597+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics SVP Finance Amy Bachrodt to resign effective June 1, 2026

## Summary
- Amy Bachrodt resigns as SVP, Finance, effective June 1, 2026.
- Resignation not related to any disagreement with the company.
- CFO Misbah Tahir will assume principal accounting officer role.

## SEC filing metadata
- accession: 0001193125-26-237199
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-05-22T21:24:41+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/d909749d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-237199
- JSON: https://secwatch.observer/filing/0001193125-26-237199.json
- Plain text: https://secwatch.observer/filing/0001193125-26-237199.txt

## Source-grounded claims
- claim_id: 1bd3306082
  claim: Misbah Tahir changed role as Chief Financial Officer and principal accounting officer at Maze Therapeutics, Inc..
  evidence_excerpt: Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm
- claim_id: c95279582e
  claim: Amy Bachrodt departed as Senior Vice President, Finance at Maze Therapeutics, Inc..
  evidence_excerpt: On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.